This webpage contains legacy information. The product is either no longer available from the supplier or has been delisted at Labome.
product summary
company name :
ACROBiosystems
product type :
protein
product name :
Human M-CSF R / CSF1R / CD115 Protein, His Tag (HPLC verified)
catalog :
CSR-H5228
quantity :
200 ug, 1 mg
price :
230 USD, 980 USD
product information
company name :
ACROBiosystems
product type :
Protein
catalog :
CSR-H5228
product name :
Human M-CSF R / CSF1R / CD115 Protein, His Tag (HPLC verified)
quantity :
200 ug, 1 mg
price :
230 USD, 980 USD
quantity & price :
$230/200ug,$980/1mg (250ug × 4)
target :
M-CSF R
host species :
Human
By Tag :
His Tag
Research :
For Research Use Only
Source :
Human M-CSF R, His Tag (CSR-H5228) is expressed from human 293 cells (HEK293). It contains AA Ile 20 - Glu 512 (Accession # NP_005202.2).
Endotoxin :
Less than 1.0 EU per μg by the LAL method.
Purity :
>96% as determined by SDS-PAGE.
SDS-PAGE Remark(R&NR) :
Human M-CSF R, His Tag on SDS-PAGE under reducing (R) condition. The gel was stained overnight with Coomassie Blue. The purity of the protein is greater than 96%.
Formulation :
Lyophilized from 0.22 μm filtered solution in PBS, pH7.4. Normally trehalose is added as protectant before lyophilization. Contact us for customized product form or formulation.
Reconstitution :
Please see Certificate of Analysis for specific instructions. For best performance, we strongly recommend you to follow the reconstitution protocol provided in the CoA.
Storage :
For long term storage, the product should be stored at lyophilized state at -20°C or lower. Please avoid repeated freeze-thaw cycles. This product is stable after storage at:
● -20°C to -70°C for 12 months in lyophilized state;
● -70℃ for 3 months under sterile conditions after reconstitution.
Background :
Colony stimulating factor 1 receptor (CSF1R) is also known as macrophage colony-stimulating factor receptor (M-CSFR), CD115 Cluster of Differentiation 115 (CD115), C-FMS, CSFR, FIM2, FMS, and is a member of the typeⅢ subfamily of receptor tyrosine kinases (RTKs). CSF1R is a receptor for a cytokine called colony stimulating factor 1, The protein encoded by the CSFR1 gene is the receptor for colony stimulating factor 1, a cytokine which controls the production, differentiation, and function of macrophages. This receptor mediates most, if not all, of the biological effects of this cytokine. Ligand binding activates CSFR1 through a process of oligomerization and transphosphorylation . Mutations in CSF1R are associated with chronic myelomonocytic leukemia and type M4 acute myeloblastic leukemia. Increased levels of CSF1R1 are found in microglia in Alzheimer's disease and after brain injuries. The increased receptor expression causes microglia to become more active. Both CSF1R, and its ligand colony stimulating factor 1 play an important role in the development of the mammary gland and may be involved in the process of mammary gland carcinogenesis.
References :
(1) Ridge, et al., 1990, Proceedings of the National Academy of Sciences 87 (4): 1377–80.
(2) Mitrasinovic, O. M., 2005, Journal of Neuroscience 25 (17): 4442–51.
(3) Tamimi, R. M., 2008, Cancer Research 68 (1): 18–21.
(4) Pollard, J. W., 1994, Proceedings of the National Academy of Sciences 91 (20): 9312–6.
(5) Sapi, Eva, 2004, Experimental Biology and Medicine 229 (1): 1–11.
company information
ACROBiosystems
ACROBiosystems is a leading manufacturer of recombinant proteins and other critical reagents to support the development of target therapeutics, vaccines and diagnostic kits.
Our team has worked tirelessly since the genomic sequence of SARS-CoV-2 was first published, developing a serial of critical reagents to fight COVID-19. Our team has successfully developed a new neutralizing antibody titer serologic assay kit for COVID-19 vaccine evaluation (Cat.No.TAS-K022) which really showed excellent performance.
As the emerging variants may have impacted on the development of the COVID-19 epidemic, our team is also going full steam ahead on developing a collection of spike mutants for the emerging variants of SARS-COV-2. The reagents can be used to evaluate the efficacy of the antibodies and vaccination.
We have also developed an extensive collection of recombinant proteins to support the development for bispecific antibodies, antibody drug conjugates and cell therapies.
Our team has worked tirelessly since the genomic sequence of SARS-CoV-2 was first published, developing a serial of critical reagents to fight COVID-19. Our team has successfully developed a new neutralizing antibody titer serologic assay kit for COVID-19 vaccine evaluation (Cat.No.TAS-K022) which really showed excellent performance.
As the emerging variants may have impacted on the development of the COVID-19 epidemic, our team is also going full steam ahead on developing a collection of spike mutants for the emerging variants of SARS-COV-2. The reagents can be used to evaluate the efficacy of the antibodies and vaccination.
We have also developed an extensive collection of recombinant proteins to support the development for bispecific antibodies, antibody drug conjugates and cell therapies.
questions and comments